Related Experiment Video
Updated: Jul 9, 2026
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
Immunogenicity of Rabies Virus G-Protein mRNA Formulated with Muscle-Targeting Lipid Nanoparticles in Mice
Qin Li1, Huarong Bai1, Xueliang Yu1
1Starna Therapeutics Co., Ltd., Suzhou 215123, China.
Background:
Rabies is a preventable zoonotic disease caused by the rabies virus (RABV) with a high mortality rate. Most vaccines on the market or under development have issues, such as low single-dose neutralization titer, complex processes, and high costs. During the COVID-19 pandemic, the successful development of mRNA vaccines opened up a new avenue for preventive vaccines. As a new technology, mRNA has higher scalability.
Methods:
In this study, we designed an mRNA encoding the RV-G protein, encapsulated by our own muscle-targeting lipid nanoparticles (LNPs), and evaluated the expression of the RV-G protein in vitro, its immunogenicity, and its protection against virus infection in vivo.
Results:
The results show that RV-G mRNA was significantly expressed in vitro. High Virus-IgG binding titers and virus-neutralizing antibody titers (VNT) were induced by immunization with RV-G mRNA-LNP. Additionally, our results showed that the RV-G mRNA vaccine is better than commercially available vaccines in mice.
Conclusions:
Our research highlights the potential of the mRNA-LNP platform in developing next-generation rabies vaccines.
